#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Mark Jones Email
VP, Device Development - Disposables & Platelet & Plasma Biology . Cerus
How to contact Mark Jones
Join and see Mark's contact info for free!Current Roles
Employees:
363Revenue:
$65.4MAbout
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in late stage clinical development, and the company is also developing an INTERCEPT cryoprecipitate product for the treatment of bleeding complications in trauma, maternal hemorrhage and cardiovascular surgery.Cerus Address
1220 Concord AvenueConcord, CA
United States